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Recommendations in asthma guidelines presuppose that practitioners have the evidence, information,
knowledge, and tools to select inhaler devices appropriate for individual patients. Randomised controlled
trials usually exclude patients with suboptimal inhaler technique. There is therefore little evidence on
which to base inhaler selection in the real world, where patients often use their inhalers incorrectly. The
lung deposition of inhaled drug varies according to inhaler device, drug particle size, inhalation tech-
nique, and pattern of inspiratory ﬂow. Even with training, not all patients can use their inhalers correctly
and maintain inhaler technique; patients may have inability to handle the inhaler, strong negative
preferences, or natural breathing patterns that do not match their prescribed inhaler. Therefore,
matching device to the patient may be a better course of action than increasing therapy or training and
retraining a patient to use a speciﬁc inhaler device. Several research questions require answers to meet
the goal of helping prescribers make a more informed choice of inhaler type. Is the level of drug
deposition in the lungs a key determinant of clinical short- and long-term outcomes? What should be
measured by a clinical tool designed to check inhaler technique and therefore help with device selection?
If we have a tool to help in individualising inhaler choice, will we achieve better asthma outcomes? Do
we have to reﬁne inhaler device choice for each individual, or will we get better outcomes if we select
our current best option in light of current knowledge and apply this on a population level?
 2010 Elsevier Ltd. All rights reserved.Educational aims
 To understand why drug particle size is important in
asthma management
 To understand differences in inhaler technique
 To understand how to individualize inhaler devicessly published article. DOI of
fax: þ44 (0)1224 550683.
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rved.1. Introduction
Asthma guidelines recommend individualising inhaled therapy
for each patient, taking into consideration patient preference, in
conjunction with training and regular monitoring of inhaler tech-
nique.1,2 These recommendations presuppose that clinicians, and
other healthcare providers involved with asthma management,
have the research evidence, information, knowledge, and tools to
select an inhaler device appropriate for each patient. However,
given the confusing array of available devices, healthcare providers
may not know all the key features of inhalers and their operation,
and patients often make mistakes in using their inhalers.3
An international panel of respiratory physicians, general prac-
titioners, and academics with an interest in asthma and inhalation
devices was convened in January 2009 by the International Primary
Care Respiratory Group (IPCRG) to discuss the science of inhaler
therapy as it needs to be applied in clinical practice. In particular we
aimed to highlight where further evidence is needed to provide
guidance on inhaler selection in community settings. This meeting
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Figure 1. (a) Frequency of critical handling errors made by patients with asthma and/
or chronic obstructive pulmonary disease when using four different types of dry
powder inhalers (trade names changed to types AeD). The ﬁrst attempt was made
after patients read the device instructions, and the second attempt was made after the
investigator explained device handling. Adapted from Schulte et al.13 (b) Percentage of
patients with uncontrolled asthma who failed to use their pMDIs correctly, as tested
with an Aerosol Inhalation Monitor (AIM, Vitalograph, Vitalograph, Ltd, Buckingham,
England). The second and third tests were performed after instruction on pMDI
technique. Adapted from Hardwell et al.14
J. Haughney et al. / Respiratory Medicine CME 3 (2010) 125e131126built upon prior IPCRG work on practical ways to improve asthma
control in clinical practice, which noted inhalation technique was
a major issue in achieving asthma control (Table 1).4,5
Here we review the aspects of inhaler performance and use in
primary care that materially affect outcomes and the available
evidence that exists to guide clinical decisions in these areas. This
review has enabled us to start to identify what types of further
research and technological development are needed to meet the
goal of helping prescribers to make more informed choices of
inhaler types for their patients with asthma. Many of the issues
related to inhaler therapy are similar for asthma and chronic
obstructive pulmonary disease (COPD). However, as possible
differences in inhaler therapy between asthma and COPD have not
been studied systematically, COPD is not discussed further here.
2. Do inhaler device and the way it is used make a difference?
Reviews of randomised controlled trials comparing inhaler
devices report no difference in efﬁcacy between devices.6e8
However, most of these trials were performed for licensing
purposes and thus were designed to show noninferiority or
equivalence. Of equal importance, patients enrolled in these studies
received training and must have demonstrated good inhaler tech-
nique; those with improper technique were excluded. The studies,
therefore, do not reﬂect the population of patients using inhalers.
In the real world, patients often use their inhalers incorrectly
(Fig. 1).6,9e14 Efﬁcient inhalation technique was demonstrated by
only 46e59% of patients in the studies reviewed by Cochrane et al.9
In a systematic review, the mean percentages of patients who used
their inhalers without mistakes were 63% for metered dose inhalers
(MDIs); 75% for breath-actuated MDIs; and 65% for dry powder
inhalers (DPIs).6 Errors are made not only in inhalation technique
but also in the handling of inhaler devices, such as preparation and
positioning.10,12,13 In addition, healthcare providers may not know
how to use inhalers correctly.10,11 Importantly, poor inhalation
technique can be associated with a marked (up to 50%) decrease in
the amount of drug deposited in the lung. When the administered
medication is a bronchodilator, the subsequent acute increase in
FEV1 may be lowered by one third if the device is not used prop-
erly.15e17 Furthermore, the number of errors in inhaler use and
inhalation technique has been correlated with poorer asthma
control in patients using inhaled corticosteroids (ICS).18
Each type of inhaler requires a different inhalation technique
and breathing pattern to achieve optimal delivery of drug to theTable 1
Reasons for poor asthma control identiﬁed at prior IPCRG international meeting.4
1. Wrong diagnosis or confounding illness
2. Incorrect choice of inhaler or poor technique
 Mixed device types
 Poor training
 Erosion of technique
 Unable to use the recommended inhalation method despite training
3. Unintentional or intentional nonadherence
 Low necessity: patients’ doubts regarding need for therapy
 Persistent disease but episodic symptoms
 Forgetfulness
 High concerns: patients’ concerns about side effects
4. Concurrent smoking
 Relative steroid resistance
5. Comorbid rhinitis
 Associated with worse asthma control
6. Individual variation in treatment response
7. Undertreatmentlungs. To avoid confusion, it is argued that inhaler types should not
be mixed for an individual patient.19,20 Switching of ICS inhaler
device without an accompanying consultation in general practice
has been instituted in some countries to reduce drug costs. Such
a practice may result in loss of asthma control and increased
consultations (Fig. 2),21 possibly because patients receive no
training on how to use their new device.
Recent observational data suggest that, in real life, the choice of
inhaler device is associated with differences in outcomes.22e24 It is
unclear whether these differences arise because some inhalers and
formulations are inherently ‘better’ or more forgiving of poor
technique or because of other patient-related factors.
3. Targets of inhaler therapy and particle size effects
The lung deposition of an inhaled drug varies according to
inhaler device, features of inhalation technique, and particle size.
Reported lung deposition for different inhaler devices varies greatly
from 4% for beclometasone delivered by chloroﬂuorocarbon (CFC)-
propellant MDIs to 53% for extra-ﬁne beclometasone delivered by
CFC-free hydroﬂouroalkane (HFA)-propellant MDIs.25 However,
variation in study methods and differences in how the deposition
fraction is expressed (eg, nominal dose vs. emitted dose vs. ﬁne
particle dose) make direct comparisons between devices difﬁcult.6
Moreover, inhaler device technique can substantially affect the
amount of drug delivered to the lung.9 Other factors that could
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Figure 2. Outcome of asthma treatment during study year 2 for patients whose
inhaled corticosteroid device was switched without an accompanying consultation
(switched cohort) and matched controls: percentages of patients experiencing
successful asthma treatment, partially successful treatment, and unsuccessful treat-
ment. Reprinted from Thomas et al.21
J. Haughney et al. / Respiratory Medicine CME 3 (2010) 125e131 127inﬂuence the level and extent of deposition include pharyngeal and
lower airway anatomy, severity of obstruction, homogeneity of
ventilation, and hygroscopic properties of the aerosol.
For inhaled asthma therapy to achieve optimal effects, delivery
of drug to the appropriate regions of the lung should be maximised
and deposition of drug in the oropharynx minimised. Deposition in
the large and conducting airways (down to branch 16 of the bron-
chial tree)may be preferred for bronchodilators. These agents, most
commonly b2 agonists, will have an effect if deposited in these
airways because there are b2 receptors present in conjunctionwith
smooth muscle (Fig. 3).26e28 Instead, a more uniform lung distri-
bution may be preferred for ICS to also reach the smaller peripheral
airways, important sites of airway inﬂammation in asthma.29,30
Particles will deposit in different regions of the lungs depending
on their size and the speed of the patient’s inhalation.31 Overall,
smaller inhaled particle sizes are better able to be distributed
throughout the lungs and reach the distal airways.32 In theory,
particles <1 mm can reach the peripheral airways, where they will
have some local clinical effect. Given the heterogeneous ventilation
of the lungs of people with asthma, and the differing particle sizes
of different therapies (ICS and b2 agonists), differential deposition
of these drugs might result. The clinical consequences of such
a non-homogenous distribution are unclear and need further
investigation.M
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Figure 3. Location of targets for bronchodilators. Adapted from Carstairs et al.,26 Mak
and Barnes,27 and Jeffery.28Results of recent studies suggest that delivering ICS with smaller
particle formulations is associated with better outcomes.33,34
However, it is difﬁcult to dissociate dose and deposition, and
further studies are needed.35 These formulations provide better
lung deposition with possibly improved efﬁcacy and greater
systemic delivery because of improved pulmonary delivery as well
as reduced impaction in the oropharynx. Although small particles
(w1 mm) have a greater potential to be exhaled (approximately 10%
of the dose), this is counterbalanced by high pulmonary deposition
(60%), and the net effect is that oropharyngeal deposition is
reduced (30%).36 To maintain similar efﬁcacy and safety it is,
therefore, recommended that the dose of these products is
halved.36,37 Particles 1e5 mm will reach the large and conducting
airways where they will exert their clinical effect and be subse-
quently absorbed from the lungs. Particles>5 mm tend to settle into
the mouth and oesophageal region, where they produce no clinical
effect but can potentially produce both local side effects and
systemic side effects after gastrointestinal absorption.
4. Key factors affecting delivery of drug to the lungs
4.1. Metered dose inhalers require slow and deep inhalation as well
as co-ordination
Exhalation to functional residual capacity or residual volume
should precede the inhalation.38 This translates to a full inspiratory
vital capacity, which is required for all MDIs and DPIs. For MDIs,
although good coordination is required and can be a problem for
some patients, the most important aspect of inhalation technique is
a slow (<60 L/min) and deep inhalation.39e41 In practice this
translates to a full inhalation that lasts for 2 s (small child) to 5 s
(adult). Failure to use a slow and deep inhalation is the most
common mistake made by patients using an MDI and is more
common than failure of coordination.33,42,43 Ideally, the actuator
should be pressed at the start of the inhalation; however, we now
know that the split-second coordination of actuation and inhala-
tion is less critical if the inhalation is slow39 and especially if
actuation occurs after the start of inhalation.41 Moreover, breath
holding to facilitate sedimentation at the end of the inhalation is
less critical if the inhalation is slow.39
A faster inhalation rate increases the likelihood of oropharyn-
geal deposition with an MDI.32 Larger particles tend to settle in the
oropharyngeal region with fast inhalations, whereas smaller
particles (1.5 mm) show little difference in lung and oropharyngeal
deposition whether the inhalation is fast or slow.32
4.2. Dry powder inhalers require a rapid and forcible inhalation
Before inhalation, the formulation of all DPIs has no potential for
lung deposition. It is the patient’s inhalation that transforms the
powder in a DPI into an emitted dose of particles with the appro-
priate characteristics for deposition in the lungs. When a patient
inhales through a DPI, turbulent energy inside the device is created
by the pressure drop (ΔP) that results from the interaction between
the patient’s inhalation ﬂow (Q) and the internal design of the DPI,
which translates into a resistance to airﬂow (R). Since the turbulent
energy is represented by the relationship ODP¼Q R,44 inhalation
ﬂow should not be viewed in isolation when comparing DPIs. It is,
however, correct to refer to inhalation ﬂowwith regard to one type
of DPI because the resistance will not change.
For each inhaler there is a minimum energy, hence inhalation
ﬂow, required to provide efﬁcient disaggregation of the formula-
tion. The minimum inhalation ﬂow, while not clearly deﬁned for
each device, is important because there is the potential for a patient
to receive no dose. In general, very young and elderly patients and
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Figure 4. Schematic depicting the relationship between particle emission rate from
a dry powder inhaler (DPI; capsule & reservoir/blister type) and patient inhalation
proﬁles that are usual vs. ideal for DPI dose emission. Actual shape will vary with
device used. Adapted with permission from Chrystyn and Price.45
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generate inhalation ﬂow sufﬁcient to create turbulent energy that
produces a dose reaching the lungs from some devices. However, it
should be stressed that there are some stable patients of any age
and severity of obstruction who may not be capable of generating
sufﬁcient energy inside their DPI, and so this needs to be checked
routinely for all patients.44
When a patient inhales through a DPI containing doses stored
inside the device (either in a reservoir or as single-dose blisters),
disaggregation of the powder occurs almost immediately as the
dose leaves the device. Fig. 4 depicts two possible inhalation
proﬁles generated through the same device by a patient, an ideal
proﬁle and a more usual proﬁle.45 Superimposed onto these
proﬁles is when the dose would leave a reservoir or blister DPI and
a capsule DPI. It is evident that the rate of increase in ﬂow (and
hence turbulent energy) will be greater, and the disaggregation of
the powder inside the DPI more efﬁcient, for the patient who
generates the ideal inhalation proﬁle. Failure to use a fast inhalation
from the start through a DPI results in the emission of particles that
are too big to be deposited in the lungs and so the dose is deposited
in the oropharynx and subsequently swallowed.46 If the inhalation
is too fast, which is possible for a DPI with a low resistance, the
powder may not disaggregate before it leaves the inhaler. This, as
well as the particle’s momentum in a fast moving airstream, will
lead to greater deposition in the oropharynx.Table 2
Summary of the optimal inhalation manoeuvre and key points regarding metered dose
Metered dose inhalers (MDIs)
Inhalation technique:
1. exhale gently as fully as possible,
2. begin to inhale and
3. actuate the dose,
4. continue with slow (<60 L/min) and deep inhalation over 2 s (child) to
4e5 s (adult),
5. hold breath for 10 s, or as long as possible.
 Ideal co-ordination calls for dose release (actuation) at start of inhalation.
 Good co-ordination is less critical if the inhalation is slow, but the dose
has to be released after the start of the inhalation.
 Too fast an inhalation increases the likelihood of oropharyngeal deposition.
 Patients with poor coordination of actuation and inhalation can be switched
to a breath-actuated MDI.
 MDIs can be used with spacers, large or small, although spacers score low
in patient preference.For some DPIs, a powder-containing capsule is loaded into the
device by the patient, and the dose has to be emptied from the DPI
by the inhalation manoeuvre. Inhalation volume is, therefore,
another important consideration for capsule DPIs, as pictured in
Fig. 4. It is for this reason that the patient information leaﬂet for
these DPIs directs patients to use two inhalation manoeuvres per
dose.
Optimal dose emission from a DPI, therefore, depends on the
combination of inhalation volume, inhalation ﬂow, acceleration
rate, and the inhaler. The acceleration of the inhalation ﬂow (at the
start of inhalation), whilst the most important factor, correlates to
peak inhalation ﬂow when the inhalation starts with a fast accel-
eration.46 In vitro, the ﬁne particle dose is increased at higher ﬂow
rates.47,48 As a corollary, total lung deposition in vivo is greater with
faster inhalation rates, although the fast inhalation required by DPIs
results in substantial oropharyngeal deposition even at higher
rates.49,50 Combining all the information in Fig. 4 highlights that the
generic instruction to a patient using a DPI should be to “inhale as
deep and hard as possible, from the start of the inhalation and for as
long as you can.”
The combined effect of different ﬂows, acceleration rates, and
inhalation volumes need to be studied in ‘real life’ situations. Some
limited studies have been reported using the electronic lung.51e53
However, the electronic lung involves the use of a holding
chamber, and patients in these studies were highly trained to use
each DPI and excluded if they could not use the DPIs after training.
There is therefore a need for ex vivo methods to research dose
emission from real life inhalation proﬁles. This should include
different strengths and formulations in the same inhaler device,
because the effect of any changes to these factors is not known.5. Optimising inhaler therapy
Table 2 summarises the key points regarding the inhalation
manoeuvre required when using MDIs and DPIs. Before performing
each inhalationmanoeuvre, patients should be instructed to adhere
to the manufacturer’s instruction on the preparation of the dose.
Failure to perform this correctly could result in no dose being
received irrespective of the inhalation manoeuvre. Conﬁrming
proper inhaler technique is an essential step in optimising drug
delivery to the lungs. Verbal training in proper inhaler technique,
both as a sole measure and coupled with individualised instruction
in self-management of asthma, improves outcomes for patients
with asthma, in part because of improved compliance.54e56inhalers and dry powder inhalers.
Dry powder inhalers (DPIs)
Inhalation technique:
1. exhale gently as fully as possible,
2. inhale sharply: as fast and as deeply as possible,
3. hold breath for 10 s, or as long as possible.
 DPIs are breath-actuated and require adequate acceleration on
inhalation: the patient must inhale deeply and forcibly at the start
of the inhalation.
 If the patient does not inhale fast enough or long enough:
B Not all the dose is emitted;
B Particles generated are too big to enter the lungs, resulting in
increased oropharyngeal deposition.
 If the dose is supplied in a capsule then two inhalations are required
to empty the dose.
 DPIs should not be prescribed to patients with insufﬁcient inspiratory
effort, including children <5 years old and the elderly.
 DPIs are sensitive to moisture: must store in a dry place and avoid
exhaling through the inhaler.
J. Haughney et al. / Respiratory Medicine CME 3 (2010) 125e131 129Moreover, regular assessment and reinforcement are needed to
maintain handling and inhalation technique.10
For patients who cannot coordinate actuation and inhalation
with an MDI, switching to a breath-actuated MDI may be a solu-
tion.15 However, choice of pharmacologic therapy may be limited
and the unaccustomed delivery may cause (a temporary) cough.
The use of a spacer reduces oropharyngeal deposition and can as
much as double lung deposition57 by overcoming actuation/coor-
dination difﬁculties but is the option least preferred by patients.12
On a practical note, both small and large spacers reduce oropha-
ryngeal deposition.58
For DPIs, a prolonged fast inhalation from the start is important.
This can be checked visually and in part with the use of an In-Check
Dial (Clement Clark International, Harlow, Essex, UK), to ensure that
the patient can generate a minimum effective ﬂow, which at
present is universally accepted as 30 L/min. This meter is limited in
that ﬁrstly, testing is not available for all DPIs, and secondly, it will
not give an indication of the acceleration rate. If the patient’s
natural inhalation is too fast through a particular DPI, then
switching them to a DPI with a higher resistance will reduce the
speed of their inhalation. This should improve drug distribution in
the lungs and limit oropharyngeal impaction.6. Individualising inhaler device choice
A choice of possible inhaler devices is deﬁned ﬁrst by choice of
drug, device availability, and any relevant reimbursement restric-
tions. Consideration of patient age or ability to use the inhaler may
help further reﬁne the list as, for example, children <5 years old
and some elderly patients should not be prescribed DPIs because
they cannot generate sufﬁcient inspiratory ﬂow. At this point, the
prescriber may still be left with several choices of inhaler devices.
How best to proceed?
One review of inhaler technique after training concluded that
there is no difference in the ability of patients to use DPIs or MDIs.6
However, even with training, not all patients can use their inhalers
correctly; this is true for both MDIs and DPIs.12,59 In practice there
are indications that patient preferences for devices vary and,
furthermore, that preference is linked to ability to perform good
inhaler technique, and ultimately this may inﬂuence compli-
ance.12,13 Most patients inhale too fast with an MDI,42,43 and many
inhale too slowly with a DPI.60
These ﬁndings suggest that not all patients can master the
proper technique for each type of inhaler and, in addition, that
patients may have natural inspiration patterns that do not match
their prescribed inhaler. Therefore, rather than training and
retraining a patient to use a speciﬁc inhaler device, a better course
of action could be to match a device to the patient. In other words,
instead of insisting that patients use a particular device, we should
try to match device with their behaviour. Following this logic, the
ideal patient to use an MDI is a patient who tends to use slow deep
inhalations, whereas the ideal patient to use a DPI is one who can
easily perform a rapid, deep, and prolonged inspiration.
We need a clinical tool to characterise a patient’s inhalation
pattern, check inhaler technique, and enable a match with an
inhaler device; this tool should be inexpensive and easy to use.
Furthermore, we need more complete information on inhaler
device types. For each MDI, information should include the
maximum rate and minimum length of inhalation to achieve good
lung deposition. For DPIs, research is required to deﬁne the
minimum inhalation ﬂow for each type of device and the effect of
the initial acceleration of the inhalation ﬂow. This is important
because there is the potential for patients to receive no dose into
their lungs if they do not inhale fast enough through a DPI. Thisinformation could then be matched with information generated by
the clinical tool to individualise inhaler choice.
Finally, it would be useful to better standardize the way devices
and drug-device combinations are studied and the way study
results are reported to health authorities and physicians. This
would facilitate the understanding of technical and delivery/
deposition characteristics, optimal inhalation technique, ease of
use, and patient preference.
7. Conclusions
Inhaler technique is an important factor in achieving adequate
asthma control; increasing or adding treatment is not a substitute
for adequate inhaler technique.
Key questions requiring further research are the following:
1. Towhat extent is the level of lung deposition a key determinant
of clinical short- and long-term outcomes? Do different drugs
require different levels of deposition?
2. Do devices that are easier to use produce better outcomes in
well-conducted studies?
3. What should be measured by a clinical tool designed to check
breathing pattern and/or inhaler technique?
4. If we have such tools to check breathing pattern, check inhaler
handling technique, and help in individualising inhaler choice,
will their use in inﬂuencing inhaler device choice provide
better maintenance of good inhaler technique and better
asthma outcomes? Do we have to reﬁne inhaler device choice
for each individual?
5. Or, alternatively, will we get better outcomes if we systemati-
cally select the device that we believe represents the best or the
least bad option in light of current knowledge and apply this on
a population level?Conﬂict of interest
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Educational questions
Answer the following questions:
1. About what percent of patients have efﬁcient inhaler technique
according to the Cochrane review?
a. >75%
b. 60 to 75%
c. 45 to 59%
d. 30 to 44%
2. Inhalers require eduation and reassessment of technique at
most visits.
a. True only for MDIs
b. Trued only for DPIs
c. True only for inhalers using dry powder capsules
d. True for all types.
3. Which of the following statements are true?
a. DPIs should be used with spacers
b. MDIs require rapid and forcible inhalation
c. Capsules for long acting anti-cholinergics should not be
removed by touching them
d. DPIs should be shaken before each use
4. What factor(s) determine choice of inhalers?
a. Choice of drug
b. Device availability for chosen drug
c. Cost/insurance/co-pays
d. Patient characteristics
e. All of the above
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